Deal
ABBOTT LABORATORIES acquires Vysis, Inc.
December 2001
Full acquisition
Ready
01 Scorecard
The deal at a glance
Private-market deal
ABBOTT LABORATORIES acquires Vysis, Inc.
Deal value
$30.50 per share in cash (approximately $355 million)
Sector
Diagnostics — molecular / genomic diagnostics
Date
December 2001
VectorShift
Made on VectorShift
ABBOTT LABORATORIES acquired Vysis, Inc. for $30.50 per share in cash (approximately $355 million), a transaction completed in December 2001, structured as all cash (tender offer and merger).
Vysis, Inc. operates in Diagnostics — molecular / genomic diagnostics, is based in Downers Grove, Illinois, USA. Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease.
Adds molecular and genomic diagnostic capabilities to Abbott's diagnostics franchise.
Pioneering molecular/FISH diagnostic technology that became the basis of Abbott Molecular. Became part of Abbott Molecular / Abbott Diagnostics
Advisors not disclosed
No advisory firms have been disclosed for this transaction.